Pharmagest Interactive (ENXTPA:PHA) - Share price, News & Analysis

PHA fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	4/6
Past Performance	6/6
Financial Health	5/6
Dividends	3/6

PHA Stock Overview

Pharmagest Interactive SA provides various IT solutions for the healthcare sector in Europe.

Rewards

Trading at 16.6% below our estimate of its fair value

Earnings are forecast to grow 14.6% per year

Earnings grew by 26.7% over the past year

Risk Analysis

No risks detected for PHA from our risk checks.

Pharmagest Interactive Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Pharmagest Interactive
Historical stock prices
Current Share Price	€80.70
52 Week High	€103.00
52 Week Low	€67.00
Beta	0.94
1 Month Change	0.50%
3 Month Change	13.34%
1 Year Change	-12.19%
3 Year Change	48.07%
5 Year Change	95.64%
Change since IPO	1,794.37%

Recent News & Updates

May 22

Is Now The Time To Put Pharmagest Interactive (EPA:PHA) On Your Watchlist?

Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...

Shareholder Returns

	PHA	FR Healthcare Services	FR Market
7D	4.4%	4.4%	-1.3%
1Y	-12.2%	-12.0%	-5.4%

Return vs Industry: PHA matched the French Healthcare Services industry which returned -12% over the past year.

Return vs Market: PHA underperformed the French Market which returned -5.4% over the past year.

Price Volatility

Is PHA's price volatile compared to industry and market?
PHA volatility
PHA Average Weekly Movement	3.8%
Healthcare Services Industry Average Movement	7.5%
Market Average Movement	6.1%
10% most volatile stocks in FR Market	10.4%
10% least volatile stocks in FR Market	3.6%

Stable Share Price: PHA is less volatile than 75% of French stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: PHA's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1996	1,100	Denis Supplisson	https://pharmagest.com

Pharmagest Interactive SA provides various IT solutions for the healthcare sector in Europe. It offers LGPI global services and OffiCentral solutions for managing pharmacies and their networks; OffiMSS, OffiSecure, OffiProtect, OffiPass, OffiSeen, OffiCash, Offizzy, and OffiLocker solutions for pharmacists’ business processes; and solutions for energizing the customer relationship with pharmacists comprising OffiTag, OffiTouch, OffiMédia, OffiConnect, automation systems, and customer loyalty programs. The company also provides My Pilot, an analytics and management tool; OffiLearning, an e-learning tool; and solutions for patient support and advice, such as compliance monitoring software, Multimeds, Automeds, and OffiTéléconsult, as well as pharmaceutical record and shared medical record services.

Pharmagest Interactive Fundamentals Summary

How do Pharmagest Interactive's earnings and revenue compare to its market cap?
PHA fundamental statistics
Market Cap	€1.21b
Earnings (TTM)	€34.67m
Revenue (TTM)	€187.72m

35.0x

P/E Ratio

6.5x

P/S Ratio

Is PHA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
PHA income statement (TTM)
Revenue	€187.72m
Cost of Revenue	€124.69m
Gross Profit	€63.04m
Other Expenses	€28.37m
Earnings	€34.67m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

Sep 23, 2022

Earnings per share (EPS)	2.31
Gross Margin	33.58%
Net Profit Margin	18.47%
Debt/Equity Ratio	42.0%

How did PHA perform over the long term?

See historical performance and comparison

Dividends

1.2%

Current Dividend Yield

41%

Payout Ratio

Valuation

Is Pharmagest Interactive undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

16.6%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: PHA (€80.7) is trading below our estimate of fair value (€96.72)

Significantly Below Fair Value: PHA is trading below fair value, but not by a significant amount.

Price To Earnings Ratio

PE vs Industry: PHA's PE Ratio (35x) is in line with the European Healthcare Services industry average.

PE vs Market: PHA is poor value based on its PE Ratio (35x) compared to the French market (16.4x).

Price to Earnings Growth Ratio

PEG Ratio: PHA is poor value based on its PEG Ratio (2.4x)

Price to Book Ratio

PB vs Industry: PHA is overvalued based on its PB Ratio (8.8x) compared to the FR Healthcare Services industry average (2.6x).

Future Growth

How is Pharmagest Interactive forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

4/6

Future Growth Score 4/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

14.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PHA's forecast earnings growth (14.6% per year) is above the savings rate (0.3%).

Earnings vs Market: PHA's earnings (14.6% per year) are forecast to grow faster than the French market (12% per year).

High Growth Earnings: PHA's earnings are forecast to grow, but not significantly.

Revenue vs Market: PHA's revenue (9.6% per year) is forecast to grow faster than the French market (5.8% per year).

High Growth Revenue: PHA's revenue (9.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: PHA's Return on Equity is forecast to be high in 3 years time (21.9%)

Past Performance

How has Pharmagest Interactive performed over the past 5 years?

Past Performance Score

6/6

Past Performance Score 6/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

10.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PHA has high quality earnings.

Growing Profit Margin: PHA's current net profit margins (18.5%) are higher than last year (17.1%).

Past Earnings Growth Analysis

Earnings Trend: PHA's earnings have grown by 10.2% per year over the past 5 years.

Accelerating Growth: PHA's earnings growth over the past year (26.7%) exceeds its 5-year average (10.2% per year).

Earnings vs Industry: PHA earnings growth over the past year (26.7%) exceeded the Healthcare Services industry -3%.

Return on Equity

High ROE: PHA's Return on Equity (25.8%) is considered high.

Financial Health

How is Pharmagest Interactive's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: PHA's short term assets (€116.1M) exceed its short term liabilities (€99.9M).

Long Term Liabilities: PHA's short term assets (€116.1M) exceed its long term liabilities (€60.2M).

Debt to Equity History and Analysis

Debt Level: PHA has more cash than its total debt.

Reducing Debt: PHA's debt to equity ratio has increased from 5.4% to 42% over the past 5 years.

Debt Coverage: PHA's debt is well covered by operating cash flow (90.7%).

Interest Coverage: PHA earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet

Dividend

What is Pharmagest Interactive current dividend yield, its reliability and sustainability?

Dividend Score

4/6

Dividend Score 4/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

1.18%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: PHA's dividend (1.18%) isn’t notable compared to the bottom 25% of dividend payers in the French market (1.72%).

High Dividend: PHA's dividend (1.18%) is low compared to the top 25% of dividend payers in the French market (5%).

Stability and Growth of Payments

Stable Dividend: PHA's dividends per share have been stable in the past 10 years.

Growing Dividend: PHA's dividend payments have increased over the past 10 years.

Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (41.2%), PHA's dividend payments are well covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Insufficient data to calculate cash payout ratio to determine if its dividend payments are covered by cash flows.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure

CEO

Denis Supplisson (52 yo)

0.083

Tenure

€370,876

Compensation

Mr. Denis Supplisson serves as Chief Executive Officer at Pharmagest Interactive SA since April 22, 2022. He served as Deputy Managing Director/Deputy Chief Executive Officer & Manager of the Europe Pharma...

CEO Compensation Analysis

Compensation vs Market: Denis's total compensation ($USD391.26K) is below average for companies of similar size in the French market ($USD921.08K).

Compensation vs Earnings: Denis's compensation has increased by more than 20% in the past year.

Leadership Team

Experienced Management: PHA's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

Experienced Board: PHA's board of directors are seasoned and experienced ( 11.1 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/22 00:00
End of Day Share Price	2022/05/20 00:00
Earnings	2021/06/30
Annual Earnings	2020/12/31